Show simple item record

dc.contributor.authorKhan, K
dc.contributor.authorHanna, GG
dc.contributor.authorCampbell, L
dc.contributor.authorScullin, P
dc.contributor.authorHussain, A
dc.contributor.authorEakin, RL
dc.contributor.authorMcAleese, J
dc.date.accessioned2018-07-16T09:52:00Z
dc.date.issued2013-10
dc.identifier.citationChinese journal of cancer, 2013, 32 (10), pp. 539 - 545
dc.identifier.issn1000-467X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2072
dc.identifier.eissn1944-446X
dc.identifier.doi10.5732/cjc.013.10120
dc.description.abstractDespite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but the repopulation of sensitive clones may also play a role, in which case re-challenge may be appropriate. Here, we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single institution who had previously received gemcitabine plus platinum in the first-line setting and had either partial response or a progression-free interval of longer than 6 months. In this retrospective study, the charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between January 2005 and April 2010 were reviewed. All the patients who received a combination of gemcitabine and carboplatin for re-challenge were included in the study. These patients were offered second-line treatment on confirmation of clear radiological disease progression. The overall response rate was 15% and disease control rate was 75%. The median survival time was 10.4 months, with 46% of patients alive at 1 year. These results suggest that re-challenge chemotherapy should be considered in selected patients with radiological partial response or a progression-free survival of longer than 6 months to the initial therapy.
dc.formatPrint-Electronic
dc.format.extent539 - 545
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectDisease Progression
dc.subjectCarboplatin
dc.subjectDeoxycytidine
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectNeoplasm Staging
dc.subjectDisease-Free Survival
dc.subjectRemission Induction
dc.subjectSurvival Rate
dc.subjectRetrospective Studies
dc.subjectFollow-Up Studies
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.titleRe-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.5732/cjc.013.10120
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
rioxxterms.licenseref.startdate2013-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfChinese journal of cancer
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume32
pubs.embargo.termsNot known
dc.contributor.icrauthorKhan, Khurumen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0